長鑫科技 added to DRAM ETF! Ranks as its eighth-largest holding, with a 2.52% weighting
Published ・ Source Taiwan | 鉅亨網
Chinese DRAM maker 長鑫科技 was newly included in the world's first memory-focused ETF, DRAM ETF, with a 2.52% weighting, making it the eighth-largest holding. This marks an important step in the rising international recognition of Chinese semiconductor companies.
【豐達科】Press release—豐達’s July unaudited consolidated revenue totaled 4.94億元
Published ・ Source Taiwan | 臺灣證券交易所
豐達科 reported revenue of 494 million yuan in July 2026, down 0.65% month on month but up 53.03% year on year. Revenue for the first 7 months totaled 3.084 billion yuan, up 37.31% year on year, marking significant growth.
【華孚】Press release—華孚’s unaudited consolidated revenue for July 115年 totaled NT$550 million
Published ・ Source Taiwan | 臺灣證券交易所
華孚科技 reported self-consolidated revenue of 550 million yuan for July 115, up 2.32% month on month and 1.92% year on year. Revenue for the first 7 months totaled 3.767 billion yuan, up 2.30% year on year.
[嘉威] The board meeting to review the financial report for the second quarter of 115 is scheduled for Aug. 10, 115.
Published ・ Source Taiwan | 臺灣證券交易所
嘉威 plans to hold a board meeting on Aug. 10, 115, to review its financial report for the second quarter. This is a routine financial disclosure and a material announcement; there are no other matters. Its significance lies in corporate transparency.
科定 announced that it will hold a board meeting on Aug. 10, 115, to review its consolidated financial report for the second quarter. This is a routine financial disclosure and important information for investors to track the company's financial developments.
[藥華藥] Macau's Pharmaceutical Administration has approved an additional indication for BESREMi (Ropeginterferon alfa-2b) under its “imported medicine advance approval,” for essential thrombocythemia (ET).
Published ・ Source Taiwan | 臺灣證券交易所
BESREMi from 薬華薬 received a new indication in Macau for primary thrombocythemia. This is an important step in the company's global expansion and will contribute to market growth.